Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of Rezpegaldesleukin in people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its impact on skin symptoms and severity over approximately 15 months. The goal is to better understand how this treatment influences the condition in participants who have not responded well to topical therapies. Participants will receive Rezpegaldesleukin or a placebo by subcutaneous injection during an induction period every 2 weeks. This is followed by a maintenance period with Rezpegaldesleukin given either every 4 or 12 weeks or placebo every 4 weeks. There is also an open-label escape phase where dosing frequency of Rezpegaldesleukin is adjusted by the investigator. Treatments are administered under blinded conditions during the induction and maintenance phases. During the study, participants will have their skin condition evaluated through assessments like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Other measurements include itch and skin pain scales, sleep quality, and questionnaires related to asthma and sinus symptoms. Safety is monitored by tracking adverse events through about week 56 of participation. The overall study duration for each participant is about 15 months.
Actively Recruiting
Researchers are evaluating remibrutinib in patients with chronic spontaneous urticaria CSU in a prospective, multi-country, non-interventional study. The study focuses on patients where the treatment decision to escalate current second-generation H1-antihistamines sgH1-AHs or switch to remibrutinib was made before enrollment. The goal is to collect real-world data on the effectiveness and safety of remibrutinib across diverse clinical practices, reflecting a broader patient population than typical clinical trials. The study follows an umbrella design allowing adaptations to local treatment guidelines and evidence needs across countries. Patients are grouped into cohorts based on their treatment history and decisions Cohort 1 includes those escalating sgH1-AH treatment due to inadequate control Cohort 2 includes those switching to remibrutinib Cohort 3 covers patients switching to remibrutinib with other prior treatments. Data are collected using tools like the Urticaria Control Test UCT, Urticaria Activity Score over 7 days UAS7, and Dermatology Life Quality Index DLQI. Participants will be monitored for up to 24 months with regular assessments of disease control, quality of life, angioedema activity, treatment patterns, and adverse events. Data will be gathered via electronic patient-reported outcomes and diaries to track symptoms and treatment adherence. The primary outcomes measured are UCT7 and UAS7 scores at 12 weeks after starting remibrutinib, with additional long-term measures to understand treatment effects and patient experiences.
Actively Recruiting
Researchers are evaluating remibrutinib, a new treatment option for patients with Chronic Spontaneous Urticaria CSU, in a prospective, non-interventional study. The study focuses on patients whose treatment plan before joining has already been decided to either increase their current sgH1-AH treatment or switch to remibrutinib. This US sub-study is part of a larger global program called REASSERT, which aims to collect real-world effectiveness and safety data on remibrutinib in typical clinical settings. The study observes patients divided into three groups based on their treatment history and decisions those escalating their current licensed sgH1-AH dose due to inadequate control, those switching to remibrutinib after inadequate control despite licensed or escalated sgH1-AH doses, and those switching to remibrutinib after other treatments in addition to H1-AH. Treatment decisions are made independently of the study. No interventions are assigned by the study, as it is observational. Participants will be followed for up to 24 months, during which researchers will collect data on disease control using UAS7 and UCT7 scores at 12 weeks and throughout the study. Other measures include angioedema activity, use of rescue medications, quality of life questionnaires, healthcare resource use, and adverse events. Patients will provide information electronically, and the study will evaluate treatment patterns, adherence to guidelines, and long-term outcomes.
Actively Recruiting
Researchers are studying atopic dermatitis AD in adolescents and adults to better understand the unmet needs across this condition and to observe how systemic treatments work in real-world settings. This observational study aims to explore patients journeys, including factors like age, skin color, flare triggers, past treatment responses, comorbidities, and lesion characteristics. It involves multiple countries and diverse populations to capture a broad picture of treatment impacts over time. The study follows patients who begin or switch any systemic treatment for AD, such as biologics, oral Janus kinase inhibitors, cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil, as prescribed by their doctors based on local guidelines. Researchers do not assign treatments but collect information on treatment choices and changes during standard care. This registry will track treatment sequences, interruptions, dose changes, and reasons for starting or stopping treatments over a five-year period. Participants will be followed for up to five years to monitor their treatment experience and disease progression. Data collection includes assessments of disease severity using tools like the Eczema Area and Severity Index EASI, body surface area affected, and global assessments of AD. Patient-reported outcomes such as itch, skin pain, sleep disturbance, quality of life, work productivity, and treatment satisfaction will also be recorded. Safety will be monitored through reports of adverse events. The study collects demographics, comorbid conditions, healthcare visits, and medication use to provide a comprehensive view of AD management in everyday care.